Ranbaxy Denies Plans To Trim Global Workforce Of 14,600
This article was originally published in PharmAsia News
Ranbaxy Laboratories denied reports it planned to trim its workforce in the wake of a wave of export problems.
You may also be interested in...
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.